pocketful logo light
pocketful logo light
Caplin Point Laboratories Ltd logo

Caplin Point Laboratories Ltd

NSE: CAPLIPOINT BSE: 524742

2260.80

(0.25%)

Sat, 13 Jun 2026, 07:46 am

Caplin Point Laboratories Share Price Live Chart

1 Day

(0.25%)

No Result Found

Summary

  • Market Cap (in Cr)

    15431.13

  • Net Profit (in Cr)

    541.09

  • P/B

    5.78

  • Sector P/E

    33.76

  • P/E

    28.38

  • EV/EBITDA

    19.69

  • Debt/Equity (Industry)

    0.26

  • Interest Cover (Industry)

    10.81

  • ROCE (Industry)

    16.40

  • RONW (Industry)

    14.39

  • ROE

    22.86

  • ROCE

    26.03

  • Debt/Equity

    0

  • EPS (TTM)

    84.36

  • Dividend Yield

    0.20

  • Book Value

    471.83

  • Interest Cover

    1110.48

Analysis

No Result Found

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters70.5770.5770.5770.5670.56
FII6.156.566.486.145.70
DII2.142.052.102.222.01
Public21.1420.8220.8521.0821.73
Government00000

Read More

Technical Analysis

RSI

83.52

MACD

118.89

50 DMA

1874.81

200 DMA

1904.33

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic2721.672333.172178.831944.671790.331556.171167.67
Fibonacci2333.172184.762093.071944.671796.261704.571556.17
Camarilla2131.342095.722060.111944.671988.891953.281917.66

Pivots Level: Classic

R3

+777.00

2721.67

R2

+388.50

2333.17

R1

+234.17

2178.83

1944.67
1944.67
Pivot Point
LTP: 2407.80

S1

-154.33

1790.33

S2

-388.50

1556.17

S3

-777

1167.67

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    2197.88

  • 20-EMA

    2096.84

  • 30-EMA

    2029.46

  • 50-EMA

    1946.20

  • 100-EMA

    1881.37

  • 200-EMA

    1887.40

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
14 May 2026board-meetingsAccounts, Interim Dividend
14 May 2026dividend₹4.00 Dividend /Share30 May 2026
05 Feb 2026board-meetingsQuarterly Results
05 Nov 2025board-meetingsQuarterly Results
12 Aug 2025dividendFinal Dividend - Rs. - 312 Sept 2025
07 Aug 2025agm
07 Aug 2025dividend₹3.00 Dividend /Share12 Sept 2025
15 May 2025dividend₹3.00 Dividend /Share30 May 2025
30 Apr 2025dividendInterim Dividend - Rs. - 330 May 2025
23 Aug 2024agmAnnual General Meeting24 Sept 2024

Read More

Peer Comparison

Caplin Point Laboratories Ltd logo

Caplin Point Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Caplin Point Laboratories Ltd About

Caplin Point Laboratories manufactures wide range of ointments, creams and other external application preparations in addition to the regular segments of pharmaceutical formulations.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1990

Headquarters

CEO

C C Paarthipan

Employees

Contact

Website icon

Website

http://www.caplinpoint.net

Email icon

Email

investor@caplinpoint.net; info@caplinpoint.net

Phone icon

Phone

91-44-24968000/71148000/28156653

Location icon

Location

Ashvich Towers 3rd Floor, No 3 Developed Plots Ind Estat, Chennai, Tamil Nadu, 600096

Read More

Caplin Point Laboratories Ltd Company History

YearHistory
2018
  • USFDA completed inspection at Caplin Point Lab's sterile injectable facility in Tamil Nadu
2019
  • Caplin Point Laboratories partnered with Baxter Corporation for injectable portfolio
  • USFDA completed inspection at Caplin Steriles Injectable site
  • Caplin Steriles received USFDA nod for hemorrhage prevention drug
  • Caplin Point Labs received an EIR from USFDA for injectable facility
2020
  • Caplin Point Laboratories partnered with Xellia for injectable products
  • Caplin Point Laboratories received final approval from the US drug regulator for its Abbreviated New Drug Application for Phenylephrine Hydrochloride injection
  • Caplin Steriles received USFDA approval for Verapamil Hydrochloride Injection USP
2021
  • Caplin Point arm inked a strategic partnership with Canada's JAMP Pharma Group
  • Caplin Point Laboratories arm received USFDA nod for Neostigmine Methylsulfate Injection
2023
  • Caplin Point Laboratories received the Lifetime Achievement Award 2023
  • Caplin Point Laboratories received the Forbes Asia Best Under Billion Award 2023

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
GRAVITON RESEARCH CAPITAL LLPbulkBuy3963551899.626 Aug 2024
GRAVITON RESEARCH CAPITAL LLPbulkSell3963551901.2826 Aug 2024
GRAVITON RESEARCH CAPITAL LLPbulkSell4444781763.5819 Aug 2024
GRAVITON RESEARCH CAPITAL LLPbulkBuy4444781761.7219 Aug 2024
GRAVITON RESEARCH CAPITAL LLPbulkBuy381306908.1909 Sept 2021
GRAVITON RESEARCH CAPITAL LLPbulkSell381306908.5409 Sept 2021
GRAVITON RESEARCH CAPITAL LLPbulkBuy414981957.6227 Jul 2021
GRAVITON RESEARCH CAPITAL LLPbulkSell414981957.3727 Jul 2021
XTX MARKETS LLPbulkSell460816910.5826 Jul 2021
XTX MARKETS LLPbulkBuy464203908.9126 Jul 2021

Read More

Caplin Point Laboratories Ltd News

Caplin Point to meet investors

Caplin Point Laboratories will attend the TRINITY INDIA 2026 conference on May 28, 2026, in Mumbai. The company will engage with analysts and institutional investors.

22 May 2026

companies

Caplin Point Q4 FY26 Earnings Call Audio Now Available

Caplin Point Laboratories confirms the audio recording of its Q4/FY2026 earnings call, held on May 14, 2026, is now available on the company's website.

15 May 2026

companies

Caplin Point Labs Eyes Canada, Australia & MENA Expansion

Caplin Point Laboratories aims to expand into new regulated markets including Canada, Australia, MENA, Russia/CIS, and larger LATAM markets such as Mexico and Brazil.

14 May 2026

companies

Caplin Point Labs FY26 PAT ₹650 Cr, Up 20.1% YoY

Caplin Point Laboratories reported FY26 consolidated PAT of ₹650 Cr, up 20.1% YoY. Total revenue grew 13.2% to ₹2,303 Cr. Board declared ₹4 interim dividend; record date May 30, 2026.

14 May 2026

companies

Caplin Point Labs FY26 PAT ₹650 Cr, Up 20.1% YoY

Caplin Point Laboratories reported FY26 consolidated PAT of ₹650 Cr, up 20.1% YoY. Total revenue grew 13.2% to ₹2,303 Cr. Board declared ₹4 interim dividend; record date May 30, 2026.

14 May 2026

companies

Read More

Open Your Free Demat Account

Enter your phone number